PSYCHEDELIC GUIDES · GUIDE 04
MDMA
MDMA is a stimulant-entactogen — the compound in "ecstasy" or "molly" — that floods serotonin, norepinephrine, and dopamine, reliably producing euphoria, emotional openness, and reduced fear. Since the 1980s it has been studied, on and off, as a catalyst for psychotherapy rather than as a standalone drug.
This project examines psychedelic research; it does not recommend psychedelic use. Outside approved medical care and registered clinical trials, these substances are illegal in most places, uncontrolled in content and dose, and genuinely dangerous for some people. Nothing in these guides is a how-to. If you are struggling, established treatments exist — and the medication and treatment sections of this site cover many of them.
EVIDENCE REVIEW
OCTOBER 18, 2026
What the research shows
MDMA-assisted therapy for PTSD completed two Phase 3 trials with strong results, and the FDA granted it breakthrough therapy designation in 2017. In August 2024, however, the FDA declined to approve it and requested an additional Phase 3 trial, after an advisory committee raised concerns about blinding, expectancy, and safety reporting. The honest status: promising, rigorously contested, and not approved. Research continues, and since 2023 Australia has allowed limited prescribing by authorized psychiatrists for PTSD.
Risks — and who should not take them
MDMA raises heart rate, blood pressure, and body temperature; overheating, dehydration — or drinking too much water — and heart strain have caused deaths, especially in hot, crowded settings and with repeated dosing. Combining it with MAOIs is dangerous, and serotonergic combinations, including some antidepressants, carry serotonin-syndrome risk; SSRIs may also blunt MDMA's effects, which tempts dangerous redosing. People with heart conditions, psychotic disorders, or bipolar disorder face elevated risk. Street "molly" is frequently adulterated.
Legal status
MDMA is a US federal Schedule I substance, illegal outside approved research and trials. Australia's authorized-prescriber pathway for PTSD (2023) is a narrow international exception, not general legalization.
